BIOMAT Database Logo BIOMAT Database Logo

Daunorubicin, cytosine arabinoside, 6-mercaptopurine riboside, and prednisolone (DCMP) combination chemotherapy for acute myelogenous leukemia in adults. 1975

R Ohno, and M Hirano, and K Imai, and K Koie, and T Kamiya, and H Nishiwaki, and J Ishiguro, and T Uetani, and F Sako, and K Imamura
First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan.

Thirty-seven adults with acute myelogenous leukemia (AML) were treated with a combination of daunorubicin, cytosine arabinoside, 6-mercaptopurine riboside, and prednisolone (DCMP) for remission induction. Twenty-three of 37 patients (62.2%) achieved complete remission, three, partial remission and 11, failure. Patients with prior therapy responded as well as patients without it. The median survival time of the patients who received DCMP for their initial remission induction therapy was 10.3 months and that of the patients who obtained complete remission was 17 months. Complete remission occurred in 21 out of 28 patients (75%) less than 40 years old but in only two out of nine patients (22.2%) more than 40 years old. The most common toxic effects were severe myelosuppression and liver function abnormalities. DCMP therapy is an effective remission induction chemotherapy for adults with AML.

UI MeSH Term Description Entries
D007288 Inosine A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose. It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules. (Dorland, 28th ed)
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D012075 Remission, Spontaneous A spontaneous diminution or abatement of a disease over time, without formal treatment. Spontaneous Healing,Spontaneous Regression,Spontaneous Remission,Healing, Spontaneous,Regression, Spontaneous,Spontaneous Healings,Spontaneous Regressions
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R Ohno, and M Hirano, and K Imai, and K Koie, and T Kamiya, and H Nishiwaki, and J Ishiguro, and T Uetani, and F Sako, and K Imamura
[Quadruple combination chemotherapy of acute leukemia using daunomycin, cytosine arabinoside, 6-mercaptopurine riboside and prednisolone].
December 1972, [Rinsho ketsueki] The Japanese journal of clinical hematology,
R Ohno, and M Hirano, and K Imai, and K Koie, and T Kamiya, and H Nishiwaki, and J Ishiguro, and T Uetani, and F Sako, and K Imamura
[Intensive induction chemotherapy of adult acute myelogenous leukemia by continuing daunorubicin, behenoyl-cytosine arabinoside, 6-mercaptopurine and prednisolone until marrow aplasia].
August 1992, Gan to kagaku ryoho. Cancer & chemotherapy,
R Ohno, and M Hirano, and K Imai, and K Koie, and T Kamiya, and H Nishiwaki, and J Ishiguro, and T Uetani, and F Sako, and K Imamura
Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length.
December 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R Ohno, and M Hirano, and K Imai, and K Koie, and T Kamiya, and H Nishiwaki, and J Ishiguro, and T Uetani, and F Sako, and K Imamura
Combination chemotherapy with daunorubicin, cytosine arabinoside and prednisolone (DAP) in acute nonlymphocytic leukemia.
July 1981, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
R Ohno, and M Hirano, and K Imai, and K Koie, and T Kamiya, and H Nishiwaki, and J Ishiguro, and T Uetani, and F Sako, and K Imamura
Treatment of adult acute non-lymphoblastic leukemia using intermittent combination chemotherapy with daunomycin, cytosine arabinoside, 6-mercaptopurine and prednisolone-DCMP two step therapy.
January 1976, The Tohoku journal of experimental medicine,
R Ohno, and M Hirano, and K Imai, and K Koie, and T Kamiya, and H Nishiwaki, and J Ishiguro, and T Uetani, and F Sako, and K Imamura
Combination chemotherapy using L-asparaginase, daunorubicin, and cytosine arabinoside in adults with acute myelogenous leukaemia.
November 1970, British medical journal,
R Ohno, and M Hirano, and K Imai, and K Koie, and T Kamiya, and H Nishiwaki, and J Ishiguro, and T Uetani, and F Sako, and K Imamura
Conventional dose cytosine arabinoside in combination chemotherapy for acute myelogenous leukemia.
June 1987, Seminars in oncology,
R Ohno, and M Hirano, and K Imai, and K Koie, and T Kamiya, and H Nishiwaki, and J Ishiguro, and T Uetani, and F Sako, and K Imamura
Nationwide randomized comparative study of daunorubicin and aclarubicin in combination with behenoyl cytosine arabinoside, 6-mercaptopurine, and prednisolone for previously untreated acute myeloid leukemia.
January 1994, Cancer chemotherapy and pharmacology,
R Ohno, and M Hirano, and K Imai, and K Koie, and T Kamiya, and H Nishiwaki, and J Ishiguro, and T Uetani, and F Sako, and K Imamura
Behenoyl cytosine arabinoside, aclacinomycin A, 6-mercaptopurine, and prednisolone combination therapy for acute non-lymphocytic leukaemia in adults.
July 1989, European journal of haematology,
R Ohno, and M Hirano, and K Imai, and K Koie, and T Kamiya, and H Nishiwaki, and J Ishiguro, and T Uetani, and F Sako, and K Imamura
Treatment of acute myeloid leukemia of childhood with cytosine arabinoside, daunorubicin, prednisolone, and mercaptopurine or thioguanine.
November 1975, Cancer,
Copied contents to your clipboard!